• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Personalized Drug Screening for Functional Tumor Profiling

Personalized Drug Screening for Functional Tumor Profiling

9781009016933
107,10 zł
96,39 zł Zniżka 10,71 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 96,39 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD lub Pocztę Polską. Kliknij po więcej szczegółów

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni. Kliknij po więcej szczegółów

Opis
Despite considerable advances in our understanding of the biology that underlies tumor development and progression of cancer and the rapidly evolving field of personalized medicine, cancer is still one of the deadliest diseases. Many cancer patients have benefited from the survival improvements observed with targeted therapies but only a small subset of patients receiving targeted drugs experience an objective response. Because cancer is a complex and heterogeneous disease, the search for effective cancer treatments will need to address not only patient-specific molecular defects but also aspects of the tumor microenvironment. The functional tumor profiling directly measures the cellular phenotype, in particular tumor growth, in response to drugs using patient-derived tumor models and might be the next step toward precision oncology. In this Element, the authors discuss the personalized drug screening as a novel patient stratification strategy for the determination of individualized treatment choices in oncology.
Szczegóły produktu
93786
9781009016933
9781009016933

Opis

Rok wydania
2022
Numer wydania
1
Oprawa
miękka foliowana
Liczba stron
75
Wymiary (mm)
151.00 x 228.00
Waga (g)
60
  • 1. Rationale for functional profiling in oncology; 2. Tumor models in drug screening; 3. Cell-based screening platforms for personalized medicine; 4. Drug repurposing in personalized oncomedicine; 5. Clinical applications of drug screening in oncology; 6. Conclusions and perspectives; References.
Komentarze (0)